Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis

Jiang, Huiqin; Li, Q.; Yu, Shan; Yu, Yiyi; Wang, Y.; Li, W.; Cui, Yuehong; Liu, Tianshu

doi:10.1007/s12094-016-1523-z

Cited by 11 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Retrospective studies have shown that T1–3 disease, H1, R0 resection followed by systemic chemotherapy were important prognostic factors for gastric cancer patients with liver metastasis [150, 151]. In addition, it has been found that the HER2 gene amplification rate in gastric cancer patients with liver metastasis was higher and that these patients would be more likely to gain a survival benefit from anti-HER2 targeted therapy [152]. Krukenberg tumors are the metastatic lesion of gastric cancer that have been metastasized to the ovary (one or both).…”

Section: Comprehensive Treatment Of Gastric Cancermentioning

confidence: 99%

The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

Wang

Shen

et al. 2019

Cancer Communications

520

442

View full text Add to dashboard Cite

China is one of the countries with the highest incidence of gastric cancer. There are differences in epidemiological characteristics, clinicopathological features, tumor biological characteristics, treatment patterns, and drug selection between gastric cancer patients from the Eastern and Western countries. Non-Chinese guidelines cannot specifically reflect the diagnosis and treatment characteristics for the Chinese gastric cancer patients. The Chinese Society of Clinical Oncology (CSCO) arranged for a panel of senior experts specializing in all sub-specialties of gastric cancer to compile, discuss, and revise the guidelines on the diagnosis and treatment of gastric cancer based on the findings of evidence-based medicine in China and abroad. By referring to the opinions of industry experts, taking into account of regional differences, giving full consideration to the accessibility of diagnosis and treatment resources, these experts have conducted experts’ consensus judgement on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes. This guideline uses tables and is complemented by explanatory and descriptive notes covering the diagnosis, comprehensive treatment, and follow-up visits for gastric cancer.

show abstract

Section: Comprehensive Treatment Of Gastric Cancermentioning

confidence: 99%

The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

Wang

Shen

et al. 2019

Cancer Communications

520

442

View full text Add to dashboard Cite

show abstract

“…Furthermore, HER2 overexpression was significantly higher in GEJC as compared to other locations [ 26 ], and it has a high correlation with the presence of the intestinal histological type [ 27 ]. Since the intestinal type has been associated with hematogenous metastasis [ 28 ], this might be an explaining link to the positive correlation between HER2 overexpression and hepatic metastases [ 28 , 29 ]. Additionally, several studies have found a high concordance rate of HER2 expression between primary and secondary sites, which suggests that generally HER2 status remains stable during the metastatic process [ 9 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

“…Some authors even speculate that GC liver metastases are a unique clinical entity sharing the same characteristics [ 31 ], like sensitivity to HER2-targeting drugs. Hence, Tmab could reverse the poor outcome of HER2-positive GC in these young patients, particularly with liver metastases [ 29 , 32 ].…”

Section: Discussionmentioning

confidence: 99%

Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab

Schade

Koenig

Mekolli

et al. 2022

Case Rep Gastroenterol

View full text Add to dashboard Cite

Gastric cancer (GC) represents one of the most fatal neoplasms in gastrointestinal oncology and affected patients can only hope for cure in limited disease. In a metastatic situation however, patients have a worse prognosis finally resulting in cancer-related death. Some improvements were made by using intensified chemotherapy such as the FLOT protocol (5-FU, leucovorin, oxaliplatin and docetaxel). However, a breakthrough in the treatment of advanced GC has been achieved by pre-therapeutical tumor analysis for potentially targetable alterations. Microsatellite instability, PD-L1 expression, Epstein Barr virus, and human epidermal growth factor receptor-2 (HER2) overexpression or amplification are the most beneficial targets, if addressed, can prolong survival in a palliative situation. Whether the combination of these targeted therapeutics with chemotherapy can bring long-term survival or even a chance of cure in a metastatic situation is not clear. Here, we report the case of a 30-year-old man with GC and extensive metastases who was cured by anti-HER2 antibody Trastuzumab combined with the FLOT regime. Initial staging showed an exophytic Siewert type III tumor and extensive hepatic metastases. Histology resulted in gastric adenocarcinoma with HER2 overexpression (2+, FISH positive). Twelve courses of chemotherapy comprising Trastuzumab and FLOT were administered. After treatment, the extensive liver metastases had disappeared with no evidence of residual tumor growth on the CT scans. Monotherapy of Trastuzumab was continued until gastrectomy with D2 lymph node dissection and probing of liver tissue, which revealed no residual tumor cells. Five years after surgery, there is continued complete remission. In conclusion, Trastuzumab in combination with FLOT may have curative potential even for metastatic stages of HER-2-positive GC.

show abstract

“…The specific mechanisms underlying the CTCs expressing HER2 and promoting tumor cells survival in the blood circulation have not yet been fully elucidated. Supposedly, the expression of HER2 in CTCs could promote cell survival and proliferation through the PI3K/Akt and Ras/Raf/MAPK signaling pathway [ 10 , 11 ]. Banys-Paluchowski et al detected CTCs and serum HER2 (sHER2) levels using the CellSearch system and ELISA, respectively.…”

Section: Biology Of Ctcsmentioning

confidence: 99%

Survival Mechanisms and Influence Factors of Circulating Tumor Cells

Wang

Peng

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are cancer cells shed from either the primary tumor or its metastases that circulate in the peripheral blood. The CTCs are regarded as the source of tumor recurrence and metastasis and speculated as the indicators of residual tumors, thereby indicating a poor prognosis. Although CTCs play a vital role in tumor metastasis and recurrence, little is known about the underlying survival mechanisms in the blood circulation. The accumulating evidence has revealed that CTCs might survive in the peripheral blood by overcoming the mechanical damage due to shear stress, resistance to anoikis, evasion of immune destruction, and resistance to chemotherapy. The present review addresses the putative survival mechanisms underlying the formation and migration of CTCs according to their biological characteristics and blood microenvironment. In addition, the relationship between CTCs and microenvironment is illustrated, and the influencing factors related to the interactions of CTCs with various components in the peripheral blood are reviewed with respect to the platelets, immune cells, cytokines, and circulating tumor microemboli (CTM). Furthermore, the recent advances in the new treatment strategies targeting the survival mechanisms of CTCs are also discussed.

show abstract

Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis

Abstract: HER2 positivity was higher in GCLM patients. HER2 status itself was not an independent prognostic factor in GCLM patients. Trastuzumab-based therapy could significantly improve survival in HER2-positive GCLM patients.

Cited by 11 publications

References 29 publications

The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab

Survival Mechanisms and Influence Factors of Circulating Tumor Cells

Contact Info

Product

Resources

About